awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q33916329-651135D6-0E0B-406B-B6DB-229601F947FB
Q33916329-651135D6-0E0B-406B-B6DB-229601F947FB
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33916329-651135D6-0E0B-406B-B6DB-229601F947FB
5-ASA Dose-Response: Maximizing Efficacy and Adherence.
P2860
Q33916329-651135D6-0E0B-406B-B6DB-229601F947FB
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33916329-651135D6-0E0B-406B-B6DB-229601F947FB
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
551675a20e7ccdfa6c7cc2499b452cf834e66079
P2860
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial.